RLMD News and Press, Relmada Therapeutics Inc. From 08/01/23

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 PR Newswire CORAL GABLES, Fla. , Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company...

Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ne...

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central n...

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting PR Newswire CORAL GABLES, Fla. , May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing ...

2023-05-12 21:10:06 ET Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Conference Call May 11, 2023 16:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Cedric O'Gorman - Chief Medical Officer Maged She...

2023-05-11 16:17:58 ET Relmada Therapeutics press release ( NASDAQ: RLMD ): Q1 GAAP EPS of -$0.87 beats by $0.02 . As of March 31, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $132.4 million, compared to cash, cash equivalen...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results PR Newswire CORAL GABLES, Fla. , May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ...

Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023 PR Newswire CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company add...

2023-04-19 19:28:02 ET Summary RLMD's Q4'22 earnings call came with details of changes to its RELIANCE II study in adjunctive major depressive disorder and news of an additional ~300-patient study in the same indication. RELIANCE II already has 100 patients enrolled and is enrolli...

2023-03-24 14:28:18 ET Relmada Therapeutics ( NASDAQ: RLMD ) is making "critical changes" to a phase 3 trial of REL-1017 as an adjunct treatment for major depressive disorder. The changes are being made to the Reliance II trial, the second of two late-stage trials. ...